Relevant bibliographies by topics / CML, TKI, AOEs, cytokines

Contents

  1. Journal articles
  2. Dissertations / Theses

Academic literature on the topic 'CML, TKI, AOEs, cytokines'

Author: Grafiati
Published: 14 March 2023
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'CML, TKI, AOEs, cytokines.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "CML, TKI, AOEs, cytokines"

1

Sicuranza, Anna, Ilaria Ferrigno, Elisabetta Abruzzese, et al. "Pro-Inflammatory and Pro-Oxidative Changes during Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study)." Blood 138, Supplement 1 (2021): 1479. http://dx.doi.org/10.1182/blood-2021-152530.

Full text
Abstract:
Abstract Background: Tyrosine kinase inhibitors (TKI) may offer a normal life expectancy to Chronic Myeloid Leukemia (CML) patients. However, during treatment with nilotinib, a higher than expected incidence of arterial occlusive events (AOEs) was observed. We retrospectively showed an "inflammatory status" during nilotinib treatment that may explain this increased incidence of AOEs. Here, we report results of a prospective multicenter (KIARO) study including 186 CML patients (89 imatinib, 59 nilotinib, 38 dasatinib) in which pro/anti-inflammatory cytokines were measured at diagnosis and durin
APA, Harvard, Vancouver, ISO, and other styles
2

Levy, Moshe Yair, Lin Xie, Yuexi Wang, et al. "Real-World Comparisons of Cardiovascular Events between Different Tyrosine Kinase Inhibitors Among Patients with Chronic Myeloid Leukemia." Blood 132, Supplement 1 (2018): 3567. http://dx.doi.org/10.1182/blood-2018-99-113490.

Full text
Abstract:
Abstract INTRODUCTION: Chronic myeloid leukemia (CML) is a bone marrow and blood disorder accounting for 15% of adult leukemia. A shift in CML management has occurred over the past decade with the introduction of tyrosine kinase inhibitors (TKIs), changing CML status from fatal to a chronic, lifelong illness. However, an association between TKI use and cardiovascular events has been observed. This study aimed to compare major adverse cardiac events (MACE), arterial occlusive events (AOEs), and venous thrombotic events (VTEs) among CML patients in chronic phase (CP-CML) treated with different T
APA, Harvard, Vancouver, ISO, and other styles
3

Kantarjian, Hagop M., Javier Pinilla-Ibarz, Philipp D. Le Coutre, et al. "Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts)." Journal of Clinical Oncology 35, no. 15_suppl (2017): 7012. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.7012.

Full text
Abstract:
7012 Background: The tyrosine kinase inhibitor (TKI) ponatinib has potent activity against native and mutant BCR-ABL1 and is approved for use in pts with relapsed/intolerant CML or Ph+ ALL, or with BCR-ABL1/T315I. Methods: In the pivotal PACE study (NCT01207440), ponatinib (starting dose 45 mg/d) was assessed in pts with CML or Ph+ ALL resistant/intolerant to dasatinib or nilotinib, or with T315I. In Oct ’13, dose reductions were implemented due to observed arterial occlusive events (AOEs). Efficacy and safety at 5 yrs (data as of 3 Oct ’16) for CP-CML pts are reported. Results: Of 270 CP-CML
APA, Harvard, Vancouver, ISO, and other styles
4

Levy, Moshe Yair, Lin Xie, Yuexi Wang, et al. "Major Adverse Cardiac, Arterial Occlusive, and Venous Occlusive Events Among Chronic Myeloid Leukemia Patients Prescribed Ponatinib Vs Bosutinib." Blood 134, Supplement_1 (2019): 4751. http://dx.doi.org/10.1182/blood-2019-129053.

Full text
Abstract:
INTRODUCTION: Chronic myeloid leukemia (CML) is a bone marrow and blood disorder accounting for 15% of adult leukemia. Tyrosine kinase inhibitors (TKIs) have been the standard of care for CML treatment. However, an association between TKI use and cardiovascular events has been observed. Ponatinib and bosutinib are introduced to provide more options for patients who failed their first-line treatment. The incidence of major adverse cardiac events (MACEs), arterial occlusive events (AOEs), and venous occlusive events (VOEs) were assessed among CML patients who were prescribed ponatinib vs bosutin
APA, Harvard, Vancouver, ISO, and other styles
5

Cortes, Jorge E., Jane Apperley, Elza Lomaia, et al. "OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponatinib (PON)." Journal of Clinical Oncology 39, no. 15_suppl (2021): 7000. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.7000.

Full text
Abstract:
7000 Background: PON, a third-generation tyrosine kinase inhibitor (TKI), demonstrated deep and long-lasting responses and survival in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) resistant/intolerant to second-generation TKI therapy (PACE; NCT01207440); post hoc analysis suggested a relationship between dose and both adverse events and response. Here we present the primary analysis of OPTIC (NCT02467270), an ongoing, randomized, phase 2 trial with a novel response-based dosing regimen of PON in pts with resistant/intolerant CP-CML. Methods: Pts with CP-CML resistant/int
APA, Harvard, Vancouver, ISO, and other styles
6

Caocci, Giovanni, Olga Mulas, Elisabetta Abruzzese, et al. "Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Ponatinib in the Real-Life Practice: Prophylaxis and Identification of Risk Factors." Blood 132, Supplement 1 (2018): 3006. http://dx.doi.org/10.1182/blood-2018-99-111502.

Full text
Abstract:
Abstract Background . Arterial occlusive events (AOEs) represent emerging complications in chronic myeloid leukemia (CML) patients treated with ponatinib, with a cumulative incidence correlated with the higher dose of the drug and longer treatment duration. Current recommendations highlight the importance of a careful evaluation of cardiovascular (CV) risk factors at baseline.Moreover, a preventive strategy with primary prophylaxis based on aspirin still remains under discussion and no data have been reported on secondary prophylaxis. Methods. We investigated a consecutive series of adult CML
APA, Harvard, Vancouver, ISO, and other styles
7

Ito, Tomoki, Nobuhiko Uoshima, Yasuhiro Maeda, et al. "Evaluation Of Large Granular Lymphocytes and Endothelial-Cell-Related Biomarkers In Patients With Chronic Myeloblastic Leukemia: Comparison Among 3 TKIs." Blood 122, no. 21 (2013): 5167. http://dx.doi.org/10.1182/blood.v122.21.5167.5167.

Full text
Abstract:
Abstract Background Tyrosine kinase inhibitors (TKIs) currently represent the main therapy for chronic myeloblastic leukemia (CML). Although they are therapeutically effective, some TKI-related events such as pleural effusion and elevation of large granular lymphocytes (LGL) have been reported. In addition, these events itself may affect the therapeutic response to TKIs. In the present study, we measured the levels of some cytokines, chemokines, soluble factors and coagulation markers in patients with CML, and investigated the relationship between these markers and TKI-related events. Methods
APA, Harvard, Vancouver, ISO, and other styles
8

Takaku, Tomoiku, Yoshitsugu Kojima, and Yoshiaki Yanai. "Analysis of Arterial Occlusive Events (AOE) in CML Patients Using Real-World Data : A Large Cohort." Blood 144, Supplement 1 (2024): 4538. https://doi.org/10.1182/blood-2024-201854.

Full text
Abstract:
Background While the prognosis of chronic myeloid leukemia (CML) has been significantly improved by the development of tyrosine kinase inhibitors (TKIs), the importance of managing various adverse events associated with long-term TKI treatment is increasing. In particular, arterial occlusive events (AOEs) can be fatal and potentially cause irreversible sequelae in patients, requiring the choice of TKIs according to individual patient risk and proactive therapeutic interventions for prevention. In this study, we conducted an analysis using data from the DPC database, MDV (Medical Data Vision Co
APA, Harvard, Vancouver, ISO, and other styles
9

Jedema, Inge, Linda van Dreunen, Roelof Willemze, and J. H. Frederik Falkenburg. "Treatment with Tyrosine Kinase Inhibitors May Impair the Potential Curative Effect of Allogeneic Stem Cell Transplantation." Blood 114, no. 22 (2009): 857. http://dx.doi.org/10.1182/blood.v114.22.857.857.

Full text
Abstract:
Abstract Abstract 857 Tyrosine kinase inhibitors (TKI) like imatinib and dasatinib are the current treatment of choice for patients with chronic myeloid leukemia (CML). Although most patients enter a complete remission during treatment, cure of the disease is usually not achieved since recurrence of the disease is seen in the majority of patients upon discontinuation of the treatment, indicating that the leukemic stem cell is not efficiently targeted. Furthermore, in accelerated phase and blast crisis of CML TKI treatment only results in temporary control of the disease. In these situations al
APA, Harvard, Vancouver, ISO, and other styles
10

Yu, Lu, Huifang Wang, Xiaoli Liu, et al. "Ponatinib 2-Year Efficacy, Safety and Health-Related Quality of Life in Patients with Philadelphia Chromosome-Positive Leukemia: An Open-Label, Multicenter, Phase 2 Clinical Trial in China." Blood 144, Supplement 1 (2024): 6602. https://doi.org/10.1182/blood-2024-208258.

Full text
Abstract:
Background: Ponatinib is a potent BCR::ABL1 tyrosine kinase inhibitor (TKI) effective against all single-mutation variants of BCR::ABL1, including the T315I mutation. The phase 2 clinical trial (NCT04233346) evaluated the efficacy and safety of ponatinib in Chinese patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who were resistant or intolerant to dasatinib or nilotinib, or who had the BCR::ABL1 T315I mutation. Objective: The objective of this study was to assess the efficacy, safety, and health-related quality of life (HR
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "CML, TKI, AOEs, cytokines"

1

Ferrigno, Ilaria. "Prospective evaluation of pro/anti-inflammatory cytokines during TKI treatment in chronic myeloid leukemia patients." Doctoral thesis, Università di Siena, 2021. http://hdl.handle.net/11365/1133250.

Full text
Abstract:
Chronic myeloid leukemia (CML) treatment with tyrosine kinase inhibitors (TKIs) has been associated to an increased risk of Arterial Occlusive Events (AOEs), mainly with nilotinib, but the mechanisms underlying these events have been not clarified yet. Previously, we confirmed in our retrospective cross-sectional study a higher cardiovascular (CV) risk in nilotinib treated patients, particularly if harboring the unfavorable OLR1 polymorphism and we found a nilotinib-associated pro-inflammatory effect. We started a multicenter prospective study of tyrosine Kinase Inhibitors induced pro-Athe
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'CML, TKI, AOEs, cytokines' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography